The clinical course of cerebral cavernous malformations is highly unpredictable, with few cross-sectional studies correlating proinflammatory genotypes and plasma biomarkers with prior disease severity.
C erebral cavernous malformations (CCMs) are a common cerebrovascular pathology predisposing 0.5% of the population, predisposing to a lifetime risk of intracerebral hemorrhage, seizures, and progressive focal neurological deficits.
1,2 A sporadic form of the disease, with solitary lesions, accounts for almost two thirds of cases, whereas a familial form manifests multifocal lesions developing throughout the patient's lifetime in different regions of the brain. The familial phenotype is associated with an autosomal dominant Mendelian inheritance with germ line mutations at 1 of the 3 CCM gene loci (CCM1/KRIT1, CCM2/MGC4607, and CCM3/PDCD10). 3 The lesions harbored in the 2 forms are histologically indistinguishable and consist of clusters of thin-walled blood-filled vascular caverns lined by endothelium and lacking mature vessel wall angioarchitecture. 4, 5 Endothelium of sporadic and familial lesions harbors somatic mutations in 1 of the 3 documented CCM genes, indicating common pathogenesis mechanisms. 5 CCM genes encode proteins involved in maintaining endothelial barrier integrity by inhibiting ROCK (RhoA-associated kinase) activation. 6 A loss of CCM gene function results in increased ROCK activity leading to endothelial cell-cell junction dysregulation and defective vascular permeability. 3 Experimental evidence also suggests a complex interplay between vascular permeability, inflammatory, and angiogenic processes in the neuroglial milieu as central features of CCM. 7 Acute lesional bleeding or proliferative hemorrhagic expansion results in clinically significant sequelae. However, the molecular mechanisms underlying such relevant lesional activity remain unclear, and the behavior of CCMs remains highly variable and unpredictable. Proinflammatory gene variants have been associated with higher lesion counts in cases with common familial CCM1 (Q455X) mutation. 8, 9 Our group has also reported associations of brain vascular permeability 1, 10 and clustered proinflammatory biomarkers in peripheral blood plasma 7, 11 with cumulative CCM disease severity during a patient's life. Yet specific biomarker signatures predicting subsequent clinically relevant disease behavior would be the most relevant clinically and have remained elusive. Herein, we studied the prognostic association between the plasma levels of a panel of inflammatory and angiogenic proteins previously related to CCM disease pathobiology 7 and the occurrence of a CCM-related clinically significant event in the subsequent year.
Methods
Because of the sensitive nature of the data collected for this study, requests to access the data set from qualified researchers trained in human subject confidentiality protocols may be sent to the University of Chicago Medicine to I.A.A. (e-mail: iawad@uchicago.edu).
Patient Recruitment
From July 2014 to February 2018, 172 consecutive CCM subjects were evaluated clinically at a single referral center and enrolled in biomarker studies (www.uchospitals.edu/ccm). Of these, 77 CCM subjects (42 sporadic and 35 familial) were followed for 1 year (±30 days) after biomarker collection and considered as 2 independent cohorts based on their period of enrollment. The first cohort (group 1 algorithm definition) included 49 patients enrolled and biomarkers collected between July 2014 and May 2016. The second cohort entitled group 2 algorithm testing included an additional 28 patients enrolled between June 2016 and February 2018 (Online Figure I ; Online Table I ).
All patients involved in this study gave written informed consent in accordance to the Declaration of Helsinki and approved by the University of Chicago Institutional Review Board. The ethical principles guiding the institutional review board are consistent with the Belmont Report and comply with the rules and regulations of the Federal Policy for the Protection of Human Subjects (56 FR 28003).
As per currently accepted disease categorization, cases were classified as sporadic if they harbored a solitary lesion on the most sensitive susceptibility-weighted magnetic resonance imaging sequences or a cluster of lesions associated with a developmental venous anomaly. They were classified as familial if they harbored multifocal CCMs, a family history of CCM in a first-degree blood relative, or a mutation genotyped at a CCM gene locus. Patients with partial or complete CCM lesion resection or any prior brain irradiation were excluded. 1, 7, 10 The best weighted combination of biomarkers to predict subsequent disease activity within 1 year (±30 days) was defined in group 1 algorithm definition and then tested in group 2 algorithm testing.
For each patient enrolled in the study, the aforementioned features were assessed during the clinical follow-up visit. These were reviewed and adjudicated by the senior author with experience in the care of CCM (I.A.A.), blinded to any knowledge about the biomarker levels and electronically stored in a secure database for subsequent analysis. For more methodological details, refer to the Online Data Supplement. 
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Novelty and Significance
What Is Known?
• Cerebral cavernous malformation (CCM) is a common neurovascular pathology affecting 0.5% of the population worldwide.
• The clinical course of CCMs is highly unpredictable.
• The central and systemic inflammatory processes influence the pathogenesis and progression of CCMs.
What New Information Does This Article Contribute?
• It is the first study reporting a mathematical model predicting shortterm subsequent clinical CCM lesional activity.
• This model may play a direct role in selecting patients with CCM for aggressive therapies and in the stratification of cohorts in clinical trials.
• These results may be critical to define biological targets for therapies.
Herein, we report a predictive association between plasma biomarkers and subsequent lesional clinical activity. Our results support an extensive literature on the influence of inflammatory and angiogenic processes in the pathobiology of CCM disease. They also define a likelihood-based computational model to predict short-term future clinical activity based on a panel of preselected inflammatory and angiogenic cytokines. If validated in multisite studies, this model may play a direct role in selecting patients for aggressive therapies and in the stratification of cohorts in clinical trials. The same approach may be useful in other cerebrovascular pathologies, including hemorrhagic microangiopathy, amyloid angiopathy, and aging, where similar mechanisms have been postulated.
Results
Demographic and CCM Lesion Characteristics
In the first cohort (group 1 algorithm definition), 11 of the 49 subjects manifested a hemorrhagic expansion. One subject experienced a new symptomatic hemorrhage from a known CCM per adjudicated criteria, 12 5 developed lesional growth by >3 mm diameter on T 2 -weighted magnetic resonance imaging sequences, and 5 had both symptomatic hemorrhage and lesional growth during the subsequent year after biomarker collection.
2,10 Thirty-eight subjects (78%) did not experience any change in CCM lesions during the same period and were defined as stable.
In the second cohort (group 2 algorithm testing), 7 of the 28 subjects experienced hemorrhagic expansion as described previously (2 subjects experienced a new symptomatic hemorrhage; 3, a lesional growth; and 2, both) within 1 year after biomarker collection.
Among the familial cohort, 8 subjects developed new lesions on the most sensitive magnetic resonance imaging susceptibility-weighted imaging. Cases with hemorrhagic expansion had higher T 2 -weighted (P=0.001) and total (P=0.002) lesion counts and nonsignificant trends toward higher prevalence of brain stem lesion location and recent symptomatic hemorrhage in the prior year. There were no significant differences in the age, sex, or mean follow-up time between the stable subjects and the ones who experienced a hemorrhagic expansion within the year after the blood sample. However, the cohort of familial cases that developed new lesions within a year was older than familial patients that did not (P=0.02).
Soluble CD14 (cluster of differentiation 14; sCD14), VEGF (vascular endothelial growth factor), and IL (interleukin)-6 plasma levels were lower, whereas IL-1β and soluble ROBO4 (roundabout guidance receptor 4; sROBO4) were higher in subjects who experienced clinical lesional activity within the year after the initial blood sample.
After correction for batch effect when appropriate, subjects experiencing a hemorrhagic expansion showed lower plasma levels of sCD14 (P=0.05), IL-6 (P=0.04), and VEGF (P=0.0003), along with higher IL-1β (P=0.008) and sROBO4 (P=0.03) plasma levels (Online Figure II) . There were no potential confounders affecting the plasma levels of the 24 biomarkers, such as age of enrollment, phenotype (solitary/ sporadic or multifocal/familial), genotype (sporadic, CCM1, CCM2, or CCM3), or sex (male or female). In addition, plasma levels of these biomarkers were not associated with brain stem lesion location or symptomatic bleed within the preceding year, known risk factors of lesional activity. 4 We did not identify significant association between the formation of new CCMs and the plasma levels of any of the selected biomarkers in the familial cohort.
The combination of sCD14, IL-1β, VEGF, and sROBO4 is the best predictor of a future lesional activity.
The receiver operating characteristic curves for sCD14 
The receiver operating characteristic analysis differentiated subjects who experienced a lesional hemorrhagic expansion from stable subjects with a sensitivity of 86% and specificity of 88% (Figure [B] ). Further analysis showed that the mean estimated combination value (Equation 1) was 5-fold higher (P<0.0001) in subjects who experienced hemorrhagic expansion (mean estimated value, 1.67±1.13) within the following year compared with subjects who remained . B, The receiver operating characteristic curve generated for the best linear combination was able to predict a clinical lesional activity within a year (±30 d; area under the curve [AUC], 0.90; P=0.0001) with a sensitivity of 86% and specificity of 88%. C, The mean estimated combination value was 5-fold higher in subjects who experienced a hemorrhagic expansion than stable cases (P<0.0001).
stable (mean estimated value, −0.39±0.59; Figure [C] ). The mean estimated combination value calculated with the best model was also 3-fold higher (P<0.01) in patients of the independent cohort (ie, group 2 algorithm testing) who experienced a subsequent hemorrhagic expansion. In addition, the logistic regression analysis showed that the best linear combination was able to correctly predict the subsequent respective stable or hemorrhagic expansion status in 83.3% and 75.0% of the cases in the independent cohort (Online Table III ). This result was also supported by receiver operating characteristic analysis, which showed 90% sensitivity and 71% specificity (Online Figure III) of the weighted biomarker equation predicting a hemorrhagic expansion within 1 year (±30 days) in the independent cohort.
For more results, refer to the Online Data Supplement.
Discussion
We evaluated the prognostic association between the plasma levels of 24 biomarkers and the occurrence of an impending clinically relevant lesional activity during the subsequent year. The biomarkers were selected based on a systematic literature review of demonstrated associations with relevant disease mechanisms in CCM or brain hemorrhage (Online Table IV ). 7 Results showed that the plasma levels of sCD14, IL-1β, sRO-BO4, VEGF, and IL-6 were differently expressed in subjects who experienced a CCM-related event in the year after the initial blood sample. We then calculated the Akaike information criterion-a robust and traditional likelihood-based model selection-to determine the best linear combination to predict future lesional activity. The best model was achieved by the linear weighted combination, including sCD14, IL-1β, sROBO4, and VEGF. The influence of proinflammatory genotypes and neuroinflammation in the physiopathology and clinical course of CCM disease has been described in recent years. [7] [8] [9] Singlenucleotide polymorphisms of CD14, IL1B, and IL6 genes have been associated with aggressive phenotypes of hemorrhagic cerebrovascular disease, including CCM, brain arteriovenous malformation, and aneurysm. 8, 9, 13 Recently, Tang et al 9 in collaboration with our group showed that functional gene variants causing increased expression of CD14-anchored membrane glycoprotein are associated with greater lesion counts in familial CCM1 sharing the same mutation (Q455X). Here, we report lower levels of sCD14 as a predictor of subsequent lesional activity. The association between the levels of circulating CD14 and the anchored membrane form remains unclear and may not be correlated.
14 Higher levels of sCD14 may have anti-inflammatory effects by inhibiting lipopolysaccharide-mediated functional responses. [14] [15] [16] IL-1β is a proinflammatory cytokine with a role in mediating inflammation-induced angiogenic responses that indirectly regulates the synthesis of proangiogenic factors and facilitates endothelial cell migration, proliferation, and organization into blood vessel-like structures. 17, 18 IL-1β has also been shown to increase the endothelial permeability promoting leukocyte transmigration via multiple direct and indirect pathways. 19, 20 We recently reported that an increased permeability assessed by magnetic resonance imaging at follow-up correlated with symptomatic lesional hemorrhage or growth.
10 IL-6 is a multifunctional cytokine mediating proinflammatory and anti-inflammatory processes, as well as regenerative, neural, and metabolic pathways. 21 As with CD14, SNP (single nucleotide polymorphisms) in IL6R gene has been correlated with a greater number of CCM lesions. 8 The roles of IL-6 versus IL-6 receptor in CCM lesion development and hemorrhage will require further investigation. Our results showing higher IL-1β and lower IL-6 predicting subsequent CCM clinical activity support the hypothesis that an increased endothelial permeability may occur via inflammatory mechanisms, resulting in imminent symptomatic lesional bleeding or expansion.
ROBO4 is an endogenous inhibitor of VEGF signaling expressed by vascular endothelial cells. 22, 23 This protein has been shown to dynamically maintain vascular network stability, during pathological angiogenesis and proinflammatory processes [24] [25] [26] by modulating the expression of tight junction proteins, such as ZO-1 (zona occludens-1), occludin, and claudin-5. 27 In CCM disease, lesions harbor structurally defective tight junctions 28 and decreased mRNA expression of occludin, claudin-5, and ZO-1. 29 An increase in sROBO4 may reflect proinflammatory processes enhancing endothelial permeability, consistent with its prognostic association with CCM bleeding and growth.
VEGF has direct mitogenic effects on endothelial cells and is a key regulator of angiogenesis. 17 Dysregulation of VEGF expression has been widely studied in CCM disease and has been shown to worsen the blood-brain barrier permeability and promote progression of CCM lesions. 6, 30 A modulatory effect of VEGF in the hemorrhagic brain has also been described. 7, 31, 32 However, no difference in lesional VEGF expression was observed in a study comparing unstable versus CCM lesions resected surgically. 33 Here, we observed that decreased plasma level of VEGF is a predictor of subsequent lesional hemorrhage or growth in CCM disease. This is somewhat counterintuitive and motivates a hypothesis about how lower VEGF plasma levels might reflect an imbalance in vascular integrity, associated with subsequent aggressive lesion behavior.
The combined model including weighted contribution of 4 biomarkers sCD14, IL-1β, VEGF, and sROBO4 was the best predictor of future lesional activity. The absence of co-correlation among these 4 protein levels suggests that their relative contribution to CCM lesional activity is independent and additive (Online Table V) .
Previous studies had shown that brain stem lesion location and recent symptomatic hemorrhage are predictors of future bleeding risk. 4 Also, familial cases with aggressive genotype are associated with greater lesion burden and hemorrhagic risk. 3 In our study, patients with these risk factors were also more likely to manifest prospective symptomatic hemorrhage or lesional growth. However, we noted no association of the biomarkers with these or other baseline clinical features of disease, suggesting that the biomarker prognostication was independent of these clinical features. To best explore these interactions, future studies will need to be powered to detect prognostic associations of the weakest biomarker in the smallest relevant disease subgroup.
None of the biomarkers showed association with de novo lesion genesis in familial cases. We had previously shown an association of focal brain vascular hyperpermeability with subsequent lesion genesis in that same brain region. 10 Our study included a small number of familial cases with lesion growth. If confirmed in a larger cohort, it is possible that such focal brain vascular hyperpermeability may not be reflected in our assayed biomarkers.
Our single-site study does not exclude referral bias, and cases with biomarker sampling may have undergone lesion resection or otherwise not been available for prospective followup at our center. These cases without follow-up did not have significantly different biomarker levels or clinical features, reassuring us that follow-up bias did not likely impact our results. Beyond larger sample sizes, with sufficient number of cases in relevant subgroups, future multisite studies will be designed to better control for these potential biases.
Notwithstanding these limitations, this study is the largest to date in this rare disease, and this is the first report of a strong prognostic association of a peripheral blood biomarker with clinical activity in a defined cerebrovascular pathology. We will pursue validation of these results in conjunction with multisite clinical trial readiness project already underway, funded by the United States National Institutes of Health, and in other prospective question-driven studies. These will consider specific clinical scenarios and risk versus benefit of biomarker clinical application. 34 In addition, the assay methodologies and batch effect correction have generated arbitrary units that could not be extended directly into clinical practice. Future studies will assess the differences in plasma levels between healthy controls and cohorts of patients with CCM with stable and unstable clinical activity, providing reference ranges of biomarker values applicable to positive and negative clinical prognostic risk.
The correlations herein do not imply a specific causality related to CCM disease, but they generate cogent hypotheses about mechanism of disease risk, to be pursued in future laboratory and clinical studies. Finally, the chosen biomarkers were selected based on current knowledge about CCM disease mechanims. 17 More recent investigations have highlighted additional key molecules involved in pathobiology. 9, 35 Respective biomarkers related to these novel mechanisms may further refine the predictive power of clinical behavior in this disease.
Summary
Our results support an extensive literature on the influence of inflammatory and angiogenic processes in the pathobiology of CCM disease. They define a mechanistic-based conceptual model to predict short-term future clinical activity based on a panel of inflammatory and angiogenic cytokines. If validated in multisite studies, this model may play a direct role in selecting patients for aggressive therapies and in the stratification of cohorts in clinical trials. This same approach may be useful in other cerebrovascular pathologies, including hemorrhagic microangiopathy, amyloid angiopathy, and aging where similar mechanisms have been postulated. 36 
